Attune Pharmaceuticals bags $23M for oral HAE drug by Amirah Al Idrus Wednesday, January 23, 2019 Attune Pharmaceuticals raised $23 million in series B financing to push its oral drug for hereditary angioedema through phase 2.
Mirum scoops $120M to take ex-Shire drug into phase 3 by Nick Paul Taylor Wednesday, November 7, 2018 The deal reunites some of the management team and investor syndicate that worked on the liver disease drug at Lumena before selling out to Shire.
Shire’s ophthalmic medical lead joins Kala Pharmaceuticals as VP by Conor Hale Thursday, October 25, 2018 Shire’s Steven Zhang, M.D., Ph.D., joined Kala Pharmaceuticals to lead its medical affairs work as it begins transitioning to the commercial stage.
Shire buys Swiss plasma collector Sanaplasma by Joseph Keenan Wednesday, September 12, 2018 In a move to bolster its access to plasma, Shire snapped up Swiss source plasma collection company Sanaplasma for an undisclosed price.
BioCryst says oral drug works for HAE attacks by Phil Taylor Tuesday, September 4, 2018 BioCryst says its BCX7353 drug effectively treated acute hereditary angioedema attacks in a midstage trial, setting up a possible registration study.
Shire’s fast-track NASH drug abruptly stopped in phase 2 by Ben Adams Tuesday, July 31, 2018 Shire has quietly cut the trial of an FDA fast-tracked fatty liver disease drug, although it’s not giving much away about what happened.
Enyo raises $47M to bring hep B, NASH drug to phase 2 by Conor Hale Monday, June 4, 2018 Enyo Pharma raised nearly $47 million to launch the first two phase 2 clinical trials of EYP001, its lead candidate in hep B and NASH, before 2019.
